8 news items
Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
CGTX
21 May 24
.Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
CGTX
7 May 24
-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease
CGTX
22 Apr 24
. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
CGTX
2 Apr 24
biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
CGTX
26 Mar 24
and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We
sysrl4hnd74 ylno7q4cpvk8v0ugtw4rm46kfbgu6ssled2wyg
CGTX
15 Mar 24
:Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative
mpcxt
BSFC
CGTX
EKSO
15 Mar 24
company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders
zqxqztlncceaf301aihvir3mb5j5m790pa6zy5n1ceyv6hr ovz
CGTX
11 Mar 24
in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous
- Prev
- 1
- Next